InsiderSignal.AI

InsiderSignal.ai

ZBIO - Zenas Biopharma, Inc.

Insider Purchase by Fairmount Funds Management LLC (Dir)

6 Months
After Trade
Before Trade

Loading data...

Trade Summary

4 months ago, Fairmount Funds Management LLC, serving as Dir at Zenas Biopharma, Inc. (ZBIO), purchased 316,219 shares at $19.00 per share, for a total transaction value of $6,008,161.00. Following this transaction, Fairmount Funds Management LLC now holds 2,209,025 shares of ZBIO.

This purchase represents a 17.00% increase in Fairmount Funds Management LLC's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Tuesday, October 7, 2025 and publicly disclosed via SEC Form 4 filing on Thursday, October 9, 2025, 2 days after the trade was made.

Zenas Biopharma, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider buying activity in this sector can provide valuable signals about industry trends and company-specific developments.

Fairmount Funds Management LLC

Dir

Fairmount Funds Management LLC is a Philadelphia-based registered investment adviser specializing in biotechnology and life sciences, with a focus on promising new therapies, differentiated therapeutics, and companies with robust research and experienced management.[[1]](https://rocketreach.co/fairmount-funds-management-llc-profile_b43dbb07c19c9c58)[[2]](https://www.zoominfo.com/c/fairmount-funds-management-llc/398223033)[[3]](https://fairmountfunds.com) Headquartered in Conshohocken, Pennsylvania (with some sources listing Philadelphia addresses), the firm manages over $1 billion in assets under management (AUM), reported as high as $2.5B+ in some profiles and $1.11B in recent SEC 13F filings as of Q3 2025, employing around 21-26 staff and generating approximately $3 million in annual revenue.[[1]](https://rocketreach.co/fairmount-funds-management-llc-profile_b43dbb07c19c9c58)[[4]](https://whalewisdom.com/filer/fairmount-funds-management-llc)[[5]](https://fintel.io/i/fairmount-funds-management-llc) Fairmount Funds invests in innovative biotech firms, as evidenced by its top holdings including Apogee Therapeutics (11.53%), Axsome Therapeutics (11.02%), and Enliven Therapeutics (9.65%), alongside recent activity such as adding to its position in Crescent Biopharma, Inc. (CBIO) (2.9% portfolio change, holding 16.50 million shares valued at $1.48M as of Q3 2025).[[4]](https://whalewisdom.com/filer/fairmount-funds-management-llc)[[5]](https://fintel.io/i/fairmount-funds-management-llc) As a hedge fund with 3 clients, it files as a corporate insider (e.g., Dir, 10% ownership in CBIO), supporting groundbreaking healthcare technologies through tailored investment strategies.[[1]](https://rocketreach.co/fairmount-funds-management-llc-profile_b43dbb07c19c9c58)[[2]](https://www.zoominfo.com/c/fairmount-funds-management-llc/398223033)[[4]](https://whalewisdom.com/filer/fairmount-funds-management-llc)

View full insider profile →

Trade Price

$19.00

Quantity

316,219

Total Value

$6,008,161.00

Shares Owned

2,209,025

Trade Date

Tuesday, October 7, 2025

137 days ago

SEC Filing Date

Thursday, October 9, 2025

Filed 2 days after trade

HEALTHCAREBIOTECHNOLOGY

About Zenas Biopharma, Inc.

Company Overview

No company information available
View news mentioning ZBIO

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/691720

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime